Indium In 111 Pentetate use while Breastfeeding

Summary of Use during Lactation

Information in this record refers to the use of indium In 111 pentetate as a diagnostic agent. No information is available on the use of indium In 111 pentetate during breastfeeding. Because of the long half-life of indium 111 and the potential for serious adverse reactions in nursing infants, it is best to avoid the drug in women who wish to continue breastfeeding. If the drug is given, breastfeeding should be discontinued.

Drug Levels

Indium 111 decays by electron capture with 173 keV and 245 keV gamma emissions and a physical half-life of 2.8 days.[1] The manufacturer reports that 65% of the administered dose is excreted by the kidneys within 24 hours and 85% is excreted in 72 hours.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.

Dilsizian V, Metter D, Palestro C, Zanzonico P. Advisory Committee on Medical Uses of Isotopes (ACMUI) Sub-Committee on Nursing Mother Guidelines for the Medical Administration of Radioactive Material. Final report submitted: January 31, 2019. 2019. https://www​.nrc.gov/docs​/ML1903/ML19038A498.pdf.

Substance Name

Indium In 111 Pentetate

CAS Registry Number

135998-32-2

Drug Class

Breast Feeding

Lactation

Milk, Human

Radiopharmaceuticals

Indium Radioisotopes

Diagnostic Agents